Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ICON Launches New Medical Imaging Solution for Early Phase Trials

Published: Thursday, October 25, 2012
Last Updated: Thursday, October 25, 2012
Bookmark and Share
Streamlined early phase offering designed to support faster decision making.

ICON plc, has announced the launch of a new medical imaging solution tailored to the unique requirements of early phase trials.

This new solution incorporates streamlined processes and procedures to maximize the information collected from image data and to ensure that this information is processed rapidly in line with the shorter timelines and requirements of early-phase research.

Enhanced decision making is then enabled by MIRA™, ICON’s image management system, which standardizes data from all imaging formats and allows for centralized analysis and interpretation of data.

Driving this innovation is a team of scientific and regulatory experts with deep imaging and early-phase experience to help sponsors make critical decisions about their compounds faster.

“PET, volumetrics, advanced CT and MRI are increasingly being used in early phase research which has created a demand for more tailored imaging solutions for early phase trials,” commented Ted Gastineau, President, ICON Medical Imaging.

Gastineau continued, “We have developed a unique and cost-effective solution that provides true insight to the data generated from imaging technologies and helps clients decide earlier about the future success of a drug.”

ICON Medical Imaging’s early phase group will be led by Dr. James Conklin, Senior Vice President, Medical and Scientific Affairs and Dr. Valerie Treyer, Director, Medical and Scientific Affairs, who together bring over 45 years of experience in the management of medical image data used in clinical trials.

The group will work closely with ICON Development Solutions which provides a full range of early-phase services, including clinical pharmacology, bioanalytical, PK/PD modelling and simulation, and Clinical Pharmacodynamic Models for early indications of drug efficacy.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More Than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ICON Acquires PMG Research Inc.
Acquisition enhances ICON’s site and patient engagement capabilities.
Tuesday, December 15, 2015
ICON Partners with iCardiac Technologies
ICON certified as a partner of iCardiac’s early precision QT® program.
Saturday, November 07, 2015
ICON Creates New Global Innovation Hub in Ireland
Global Innovation Hub will create 200 Scientific, IT and Business jobs in Ireland.
Thursday, February 05, 2015
ICON Selected by the FDA to Develop New PRO Measure for HABP Trials
New PRO measure being developed in conjunction with the FNIH Biomarkers Consortium.
Thursday, November 13, 2014
ICON Launches New Analytics Service for Advanced Medical Review of Laboratory Data
ICONIK Labs allows visualization, analysis and reporting on laboratory data in real time.
Tuesday, November 19, 2013
ICON Announces Appointment to Board of Directors
ICON plc today announced the appointment of Professor William Hall as a non-executive director.
Friday, February 22, 2013
ICON to Acquire Clinical Trial Services Division of Cross Country Healthcare Inc
Acquisition expands ICON’s global resourcing, FSP and safety capabilities.
Thursday, February 07, 2013
ICON Selected by Shire as Global Strategic Partner
Global strategic partner for clinical research and central laboratory services.
Monday, January 23, 2012
Scientific News
Criminal Justice Alcohol Program Linked to Decreased Mortality
Institute has announced that in the criminal justice alcohol program deaths dropped by 4.2 percent over six years.
Charting Kidney Cancer Metabolism
Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may one day be targets for therapy.
Improving Regenerative Medicine
Lab-created stem cells may lack key characteristics, UCLA research finds.
Tick Genome Reveals Secrets of a Successful Bloodsucker
NIH has announced that decipher the genome of the blacklegged tick which could lead to new tick control methods.
Head Injury Patients have Protein Clumps Associated with Alzheimer’s Disease
Scientists have revealed that protein clumps associated with Alzheimer's disease are also found in the brains of people who have had a head injury.
Exposure to Air Pollution 30 Years Ago Associated with Increased Risk of Death
Exposure to air pollution more than 30 years ago may still affect an individual's mortality risk today, according to new research from Imperial College London.
More Then 1 in 20 U.S. Children have Dizziness and Balance Problems
Researchers at NIH have found that girls have a higher prevalence of dizziness and balance problems compared to boys, 5.7 percent and 5.0 percent.
Biosensors on Demand
New strategy results in custom "designer proteins" for sensing a variety of molecules.
Low-Cost, Portable NQR Spectroscopy
A researcher at Case Western Reserve University is developing a low-cost, portable prototype designed to detect tainted medicines and food supplements that otherwise can make their way to consumers. The technology can authenticate good medicines and supplements.
Structure of Brain Plaques in Huntington's
Researchers at the University of Pittsburgh School of Medicine have shown that the core of the protein clumps found in the brains of people with Huntington's disease have a distinctive structure, a finding that could shed light on the molecular mechanisms underlying the neurodegenerative disorder.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!